Ares Financial Consulting’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Ares Financial Consulting's PTGX Position: Q3 2026 in Review
Ares Financial Consulting sold out of Protagonist Therapeutics (PTGX) in Q3 2026, closing a stake of 6 shares — an estimated $735 sold.
Ares Financial Consulting first reported a position in PTGX in Q2 2026 and held it in 1 quarter. The position peaked at $735 in Q2 2026. 376 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Ares Financial Consulting reported no remaining Protagonist Therapeutics position as of Q3 2026 after selling out during the quarter.
- Ares Financial Consulting sold 6 Protagonist Therapeutics shares in Q3 2026, an estimated $735.
- Ares Financial Consulting first reported a position in Protagonist Therapeutics in Q2 2026 and held it in 1 quarter.
- Ares Financial Consulting's Protagonist Therapeutics position peaked at $735 in Q2 2026.
- 376 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.